FASEB J. Pierce now sold as Thermo Scientific
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published as doi: 10.1096/fj.06-8050com.
 (The FASEB Journal. 2008;22:1369-1379.)
© 2008 FASEB
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
fj.06-8050comv1
22/5/1369    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Krämer, O. H.
Right arrow Articles by Heinzel, T.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krämer, O. H.
Right arrow Articles by Heinzel, T.

Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RAR{alpha}

Oliver H. Krämer1, Sylvia Müller, Marc Buchwald, Sigrid Reichardt and Thorsten Heinzel

Institute of Biochemistry and Biophysics, University of Jena, Jena, Germany

1Correspondence: Institute of Biochemistry and Biophysics, University of Jena, Philosophenweg 12, D-07743 Jena, Germany. E-mail: o.kraemer{at}uni-jena.de

The chromosomal translocation products AML1-ETO and PML-RAR{alpha} contribute to the pathogenesis of leukemias. Here, we demonstrate that both AML1-ETO and PML-RAR{alpha} are degraded by the ubiquitin-proteasome system and that their turnover critically depends on the E2-conjugase UbcH8 and the E3-ligase SIAH-1. Contrary to its role in HDAC2 degradation, the E3-ligase RLIM does not target AML1-ETO and PML-RAR{alpha} for ubiquitin-dependent elimination. RLIM rather is a substrate of SIAH-1, which indicates that these E3-ligases operate in a hierarchical order. Remarkably, proteasomal degradation of leukemia fusion proteins, in addition to the block of histone deacetylase (HDAC) enzymatic activity is a consequence of HDAC-inhibitor treatment. The former requires the induction of UbcH8 expression and each of these processes might be beneficial for leukemia treatment. Our observations shed light on the mechanism determining the interplay between E2-conjugases, E3-ligases, and their substrates and suggest a strategy for utilizing the ubiquitylation machinery in a therapeutic setting.—Krämer, O. H., Müller, S., Buchwald, M., Reichardt, S., Heinzel, T. Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RAR{alpha}.


Key Words: proteasomal degradation • RLIM • Siah-1 • UbcH8 • HDAC-inhibitor VPA






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by The Federation of American Societies for Experimental Biology.